5LRQ

BRD4 in complex with ERK5 inhibitor XMD8-92

5LRQ の概要

• エントリーDOI: 10.2210/pdb5lrq/pdb
• 分子名称: Bromodomain-containing protein 4, 2-{[2-ethoxy-4-(4-hydroxypiperidin-1-yl)phenyl]amino}-5,11-dimethyl-5,11-dihydro-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one (3 entities in total)
• 機能のキーワード: brd4, bromodomain containing protein 4, erk5, inhibitor, transcription
• 由来する生物種: Homo sapiens (Human)
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 17389.89

構造登録者

Martin, M.P.,Noble, M.E.M. (登録日: 2016-08-19, 公開日: 2017-08-30, 最終更新日: 2024-01-17)

• 主引用文献: Myers, S.M.,Miller, D.C.,Molyneux, L.,Arasta, M.,Bawn, R.H.,Blackburn, T.J.,Cook, S.J.,Edwards, N.,Endicott, J.A.,Golding, B.T.,Griffin, R.J.,Hammonds, T.,Hardcastle, I.R.,Harnor, S.J.,Heptinstall, A.B.,Lochhead, P.A.,Martin, M.P.,Martin, N.C.,Newell, D.R.,Owen, P.J.,Pang, L.C.,Reuillon, T.,Rigoreau, L.J.M.,Thomas, H.D.,Tucker, J.A.,Wang, L.Z.,Wong, A.C.,Noble, M.E.M.,Wedge, S.R.,Cano, C.; Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38 alpha and BRD4.; Eur.J.Med.Chem., 178:530-543, 2019; PubMed: 31212132; DOI: 10.1016/j.ejmech.2019.05.057

実験手法

X-RAY DIFFRACTION (1.7 Å)